BCAT1

Across TCGA pan-cancer cohorts, BCAT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCAT1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BCAT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCAT1 expression acts as an unfavorable survival marker.

PDAC, HNSC, and CCRCC are the cancer types where BCAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.401	1.000	.006	16	view →
HNSC	DFS	Median	All	0.550	0.728	.021	10	view →
CCRCC	DFS	Tertile	III,IV	0.372	0.648	.030	8	view →
LSCC	OS	Quartile	All	0.603	1.000	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCAT1–PDAC (DFS)

Open the PDAC breakdown →